The Readout Loud

350 Avsnitt

1. 308: An ASCO preview & another Duchenne trial failure

   Publicerades: 2024-05-30
2. 307: More tumult at BIO & coercive care for sickle cell patients

   Publicerades: 2024-05-23
3. 306: Live! From the STAT Breakthrough Summit West

   Publicerades: 2024-05-16
4. 305: Everything you need to know about H5N1 bird flu

   Publicerades: 2024-05-09
5. 304: Controversial brain tissue research, obesity drug sales and Novartis’ M&A drama

   Publicerades: 2024-05-02
6. 303: A new obesity startup, an acquisition gone wrong, & the future of Teledoc

   Publicerades: 2024-04-18
7. 302: Vertex's big deal, biotech's red numbers, & an industry history lesson

   Publicerades: 2024-04-11
8. 301: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise

   Publicerades: 2024-04-04
9. 300: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech

   Publicerades: 2024-03-28
10. 299: Live! From the STAT Breakthrough Summit East

    Publicerades: 2024-03-21
11. 298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

    Publicerades: 2024-03-14
12. 297: VC turmoil, GLP-1 competition, & the war on recovery

    Publicerades: 2024-03-07
13. 296: Legal insider trading, booming biotech stocks, & the next GLP-1

    Publicerades: 2024-02-29
14. 295: Humira’s legacy, CEO symbolism, and genomic surgery

    Publicerades: 2024-02-22
15. 294: Pharma goes to Washington, Alnylam's future, & Gilead's dealmaking

    Publicerades: 2024-02-15
16. 293: AI in medicine, detangling hype, and Icelandic DNA

    Publicerades: 2024-02-08
17. 292: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon

    Publicerades: 2024-02-01
18. 291: The plight of the VC, Gilead's latest setback, & more M&A

    Publicerades: 2024-01-25
19. 290: Biotech layoffs, slumping stocks, and a 2024 preview

    Publicerades: 2024-01-18
20. 289: Live! From #JPM24

    Publicerades: 2024-01-11